Last reviewed · How we verify

NCT07477054: AERO-PAS

A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System

Not yet recruiting NA Last updated 17 March 2026
What this trial tests

NA trial testing Lungpacer Diaphragm Pacing Therapy in Ventilator Induced Diaphragm Dysfunction in 120 participants. Not yet recruiting.

Timeline
1 July 2026
Primary endpoint
1 February 2028
1 February 2028

Quick facts

Lead sponsorLungpacer Medical Inc.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment120
Start date1 July 2026
Primary completion1 February 2028
Estimated completion1 February 2028

Drugs / interventions tested

Conditions studied

Sponsor

Lungpacer Medical Inc. — full company profile →

Who can join

18 and older, any sex, with Ventilator Induced Diaphragm Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single-arm, prospective, multicenter cohort study to assess the 30-day continued safety and effectiveness of the AeroPace System in patients on mechanical ventilation (MV) at least 96 hours and who have not weaned. This is a study collecting real-world data in a post-market setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lungpacer Diaphragm Pacing Therapy

Trials testing the same drug.

Other Lungpacer Medical Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07477054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing